MTD Medical Technology and Devices

What MTD Medical Technology and Devices does

MTD Medical Technology and Devices S.p.A. is a privately held med-tech group headquartered in Milan, Italy (registered office in Casnate con Bernate, Como), formed in 2018 through the business combination of Poland's HTL-Strefa and Italy's Pikdare. The group designs, develops, and manufactures medical devices for both consumers and healthcare professionals across three areas: intuitive health monitoring (blood glucose meters, blood pressure monitors, thermometers, pulse oximeters, smart health apps), painless drug delivery (pen needles, syringes, safety pen needles, passive safety needles, safety lancets, nebulizers), and everyday self-care (wound care, pain relief, foot/oral care, cold and flu remedies). Proprietary technology includes 6-bevel needle geometry, Click attachment, passive safety needle mechanisms, Low Dead Space syringes, and Blow Fill Seal saline production, supported by a portfolio of more than 300 registered patents and two R&D centers operating under the MTD Engineering innovation hub.

The group's go-to-market is a three-layer model: direct sales forces in five key markets (Italy, France, Germany, North America, India), an indirect distributor network spanning 100+ countries, and global account partnerships with selected blue-chip pharmaceutical companies for B2B device development and contract manufacturing. Manufacturing is vertically integrated across four European plants covering 135,500 sq.m — one in Italy (Pikdare at Casnate con Bernate) and three in Poland (HTL-Strefa at Bydgoszcz, Łęczyca, and Ozorków) — yielding a production capacity of more than 2.5 billion pen needles per year and approximately 10 million HTL products shipped daily. Brands include mylife (Swiss-made premium diabetes, post-Ypsomed acquisition), Droplet (fastest-growing US pen needle brand), Dropsafe (HCP safety sharps), and HTL-STREFA (hospital/laboratory lancets); the Pic Solution consumer brand was divested to Theras Group in December 2025.

MTD is the second-largest global producer of pen needles and holds an estimated 50% global market share in safety lancets and 15% in personal lancets. Recent corporate actions — the August 2024 acquisition of Ypsomed's Pen Needles and Blood Glucose Monitoring Systems businesses and the December 2025 divestiture of Pic Solution — reposition the group toward higher-value B2B drug delivery manufacturing for injectable therapies while expanding direct presence into China and India. The company is governed by Chairman Michael Kloss and led by CEO Pietro Corsano, is privately owned with no disclosed external investor backing, and holds ISO 13485:2016, FDA 510(k), and ISO 14001:2015 certifications.

Name

MTD Medical Technology and Devices

Legal name

Medical Technology and Devices S.p.A.

Website

https://mtdglobal.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

MTD Medical Technology and Devices is a privately held Italian med-tech group formed in 2018 via the merger of Pikdare (Italy) and HTL-Strefa (Poland), designing and manufacturing pen needles, syringes, safety sharps, blood glucose monitors, and self-care devices sold across 100+ countries to pharmaceutical partners and retail channels.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro industry

PRIMARYCRACAQAE

Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)

Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

SECONDARYHLACAFAL

Connected Therapeutics & Smart Drug Delivery Monitoring

Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

SECONDARYHLAFALAH

Medication Therapy Management (MTM) & Clinical Pharmacy Services

Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services

SECONDARYHSABALAB

Medication Setup & Organization (Pill Boxes/Dispill/Packaging)

Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support

Keywords

• Medical devices
• Drug delivery devices
• Pen needles
• Blood glucose monitoring
• Safety lancets

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: MTD generates revenue through the sale of medical devices including pen needles, syringes, safety sharps, blood glucose monitoring systems, and other healthcare products. Products are sold through direct presence in key markets and through distributor networks.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

MTD Medical Technology and Devices designs, manufactures, and distributes medical devices including pen needles, safety and personal lancets, blood glucose monitoring systems, syringes, and drug delivery devices for pharmaceutical partners and end consumers. The group operates four production plants in Europe (Italy and Poland), sells under proprietary brands (mylife, Droplet, Dropsafe, HTL-STREFA) and serves customers across 100+ countries.

Product overview

MTD Medical Technology and Devices is a med-tech group that designs, develops, and manufactures medical devices for both consumers/patients (home use) and healthcare professionals. The portfolio spans three core areas: (1) intuitive health monitoring (glucometers, blood pressure monitors, thermometers, pulse oximeters, smart health apps); (2) painless drug delivery (pen needles — marketed under mylife, Droplet, and HTL-STREFA brands — syringes, safety pen needles, passive safety needles, safety lancets, nebulizers); and (3) everyday medical self-care (wound care, pain relief, foot/oral care, cold & flu remedies). MTD's proprietary brands include mylife (premium Swiss-made diabetes brand covering pen needles and blood glucose monitoring systems, acquired from Ypsomed), Droplet (fastest-growing pen needle brand in North America), Dropsafe (HCP safety sharps), and HTL-STREFA (hospital/lab lancets and pen needles). MTD Engineering serves as the group's in-house innovation and development hub.

Differentiator

Problem solved

Functional benefit

Brands

• Mylife: A well-established diabetes brand licensed to MTD Group, extending to pen needles and blood glucose monitoring systems distinguished by Swiss-made design and advanced technologies.
• Droplet
• Dropsafe
• HTL-STREFA

Products and services

• mylife Consumer brand of pen needles and blood glucose monitoring systems for individuals with diabetes who self-administer injectable therapies and self-monitor blood glucose at home.
• Droplet Consumer brand of pen needles and injection devices marketed to individuals with diabetes and other chronic conditions who self-administer injectable therapies.
• Dropsafe Professional brand of safety-engineered injection devices (including safety pen needles and passive safety devices) designed to protect healthcare workers from needlestick injuries in clinical settings.
• HTL-STREFA Consumer brand of personal lancets, pen needles, and related self-care devices for individuals with diabetes and other conditions requiring capillary blood sampling and self-administered injections.
• Drug Delivery Devices Drug delivery device offering including pen needles, syringes, and related injection platforms developed and manufactured for pharmaceutical and biotech partners to support injectable therapies.
• Monitoring Devices Blood glucose monitoring systems and related diagnostic devices for individuals with diabetes and other chronic conditions requiring regular self-monitoring.
• Everyday Medical Self-Care Products Everyday medical self-care products including pen needles and lancets for individuals managing diabetes and other chronic conditions as part of their daily self-care routines.

Quantifiable outcome

• Over 2 million occupational needlestick injuries occur each year among healthcare workers worldwide
• +2 more outcomes

Named customers4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Theras GroupminorChannel Partner/ Reseller/ Distributor · 12 December 2025MTD finalized the sale of Pic Solution brand to Theras Group. Under the agreement, MTD continues to supply pen needles under a manufacturing partnership. The products will be produced at MTD's Italian facility.
• YpsomedcoreStrategic or Co-development Partner · 2 August 2024MTD acquired Ypsomed's Pen Needles and Blood Glucose Monitoring Systems businesses. This strategic acquisition strengthens MTD's position in diabetes care, enhances production capacity to over 2.5 billion pen needles, expands market reach in China and India, and supports advanced manufacturing facilities in Europe.
• HTL-StrefacoreStrategic or Co-development PartnerPolish company, world leader in designing, developing, and producing diabetes products for drug delivery and capillary blood sampling. Recognized as inventor of the 'safety lancet' category. Merged with Pikdare in 2018 to form MTD Group.
• PikdarecoreStrategic or Co-development PartnerItalian company established after spin-off from Artsana Group in 2017. Combined with HTL-Strefa in 2018 to form MTD Group. Manages production facility in Casnate con Bernate, Italy.
• Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerMTD serves as development and manufacturing partner to leading pharmaceutical companies with engineering expertise, customization capabilities, and long-standing relationships in global healthcare. Enduring collaborations built upon reliability in supply and unwavering quality.
• Global Blue-Chip Healthcare EntitiescoreChannel Partner/ Reseller/ DistributorEnduring partnerships with global blue-chip entities in medical sharps sector, built upon reliability in supply and unwavering quality. Long-term relationships anchored in exceptional service levels.

Scale indicators13 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Arkray: Japanese diagnostics and medical device company producing blood glucose monitoring systems and diabetes care consumables. Direct peer in BGM devices competing with MTD's mylife franchise globally.
• Ypsomed: Swiss diabetes care specialist that sold its pen needle and BGM businesses to MTD in 2024; now focused on autoinjectors and infusion systems for pharma partners. Former direct peer in pen needles; continues to operate in adjacent drug delivery segments and shared B2B pharma relationships.
• Owen Mumford: UK-headquartered medical device company specializing in pen needles, lancets, autoinjectors, and diagnostic devices for diabetes and injectable therapies. Direct product overlap with MTD's pen needle and safety lancet categories and competing for global pharma OEM contracts.
• Nipro: Japanese medical device and pharmaceutical glass manufacturer producing pen needles, syringes, infusion sets, and diabetes care consumables. Direct peer in pen needles and syringes with global distribution competing against MTD's HTL-STREFA and Droplet brands.
• Ascensia Diabetes Care: Swiss-headquartered diabetes monitoring company (Contour portfolio) spun out of Bayer. Direct peer in the blood glucose monitoring category where MTD competes with the mylife BGM line acquired from Ypsomed.
• Embecta: Former BD Diabetes Care business spun off in 2022, Embecta is the world's largest dedicated diabetes drug delivery company, manufacturing pen needles, syringes, and related consumables. Direct overlap with MTD's core pen needle franchise and head-to-head competition in the US market.

Broad incumbents

• ICU Medical: US medical device company (including acquired Smiths Medical) producing IV therapy, syringes, and needle-free injection systems. Broad incumbent in injection and infusion drug delivery competing with MTD in safety-engineered medical devices.
• Roche Diabetes Care: Division of Roche offering the Accu-Chek portfolio of blood glucose meters, test strips, and insulin delivery systems. Broad incumbent in BGM and diabetes management where MTD's mylife brand directly competes, particularly in Europe.
• Terumo: Japanese global medical device manufacturer with significant presence in hypodermic needles, syringes, and prefilled syringe systems. Competes with MTD across safety injection devices and serves overlapping pharma and hospital customers globally.
• Becton, Dickinson and Company (BD): Global medical technology giant with broad portfolios in injection devices, prefilled syringes, needles, and sharps injury prevention. Pre-spin-off BD was the global pen needle leader via its Diabetes Care unit (now Embecta); remains the dominant broad incumbent in injection drug delivery against which MTD competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mtd-medical-technology-and-devices

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MTD Medical Technology and Devices